Comprehensive characterization of bone marrow remodeling in lung cancer identifies tasquinimod as a potential adjuvant to anti-PD-L1 immunotherapy

Background The pivotal role of tumor infiltrating myeloid cells in response to therapy is universally recognized. Nevertheless, their main cradle being the bone marrow (BM), remains vastly understudied in lung cancer owing to the spatiotemporal complexity of hematopoiesis and hard to access anatomical location. Methods We integrated transcriptional and translational analysis using scRNA-seq, multiparameter flow cytometry, RT-qPCR, ELISA, Western blot and two-photon microscopy to characterize the medullary hematopoietic compartment in long bones from orthotopic Lewis Lung Carcinoma (LLC)-bearing mice and rib fragments from operable non-small cell lung cancer (NSCLC) patients. Results LLC-bearing mice displayed an expansion of hematopoietic stem and progenitor cells (HSPCs) with intrinsic reprogramming towards immature G1/G2 neutrophils (Neu). Lack of increased expression of the proliferation marker Mki67 in these HSPCs together with reduced p38/MAPK signaling suggested not HSPCs’ proliferative but survival potential was increased. Additionally, we found reduced levels of the HSPC retention axis CXCR4/CXCL12 in murine and human bones. An axis, previously found to characterize the mesenchymal stromal BM niche, suggesting the latter is also manipulated during lung cancer progression. Single-cell analysis further demonstrated that S100a9 , commonly associated with Neu, was upregulated across multiple non-neutrophilic populations while a restricted pattern of Lcn2 upregulation was found in specific myeloid progenitors and immature B cells. Notably, both proteins also showed an heterogeneously increased trend in patients’ rib fragments. Finally, we demonstrated that Tasquinimod, known for its S100A9 immunomodulatory effect, in combination with anti-PD-L1 immunotherapy significantly reduced tumor burden in the immunotherapy-refractory LLC model. Conclusions Lung cancer promotes emergency granulopoiesis by intrinsic HSPC reprogramming towards a less apoptotic profile with Neu bias. Our findings further suggest that the HSPC retention axis CXCL12/CXCR4 is affected, warranting further investigation into the remote manipulation of the stromal BM niche during lung cancer progression. The altered expression of S100a9 and Lcn2 across the non-neutrophilic myeloid and lymphoid hematopoietic populations identifies additional molecular alterations associated with the tumor-bearing state. Finally, Tasquinimod treatment, particularly in combination with anti-PD-L1 immunotherapy, was associated with reduced tumor burden in vivo. Together, these findings support further investigation into BM-associated alterations and their potential contribution to immunotherapy-refractory lung cancer.

Authors

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2026-11-19
DOI
https://doi.org/10.1186/s13046-026-03872-7
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comprehensive characterization of bone marrow remodeling in lung cancer identifies tasquinimod as a potential adjuvant to anti-PD-L1 immunotherapy

Sophie Hernot, Sam Floru, Lieven Depypere, Kirsten De Ridder et al.
1 links
Journal of Experimental & Clinical Cancer Research
Immune cells in cancer
article

Comprehensive characterization of bone marrow remodeling in lung cancer identifies tasquinimod as a potential adjuvant to anti-PD-L1 immunotherapy

Sophie Hernot, Sam Floru, Lieven Depypere, Kirsten De Ridder, Kiavash Movahedi, Cleo Goyvaerts, Paul De Leyn, Hatice Satilmis, Katrien Vandoorne, Tim Dreessen, Kim De Veirman, Daliya Kancheva, Isabelle Scheyltjens, Tessa De Pauw, Evelyn Calderon-Espinosa, Kathleen Van den Eynde, Mekhin Carpentier, Yanina Jansen
article en

Abstract

Background The pivotal role of tumor infiltrating myeloid cells in response to therapy is universally recognized. Nevertheless, their main cradle being the bone marrow (BM), remains vastly understudied in lung cancer owing to the spatiotemporal complexity of hematopoiesis and hard to access anatomical location. Methods We integrated transcriptional and translational analysis using scRNA-seq, multiparameter flow cytometry, RT-qPCR, ELISA, Western blot and two-photon microscopy to characterize the medullary hematopoietic compartment in long bones from orthotopic Lewis Lung Carcinoma (LLC)-bearing mice and rib fragments from operable non-small cell lung cancer (NSCLC) patients. Results LLC-bearing mice displayed an expansion of hematopoietic stem and progenitor cells (HSPCs) with intrinsic reprogramming towards immature G1/G2 neutrophils (Neu). Lack of increased expression of the proliferation marker Mki67 in these HSPCs together with reduced p38/MAPK signaling suggested not HSPCs’ proliferative but survival potential was increased. Additionally, we found reduced levels of the HSPC retention axis CXCR4/CXCL12 in murine and human bones. An axis, previously found to characterize the mesenchymal stromal BM niche, suggesting the latter is also manipulated during lung cancer progression. Single-cell analysis further demonstrated that S100a9 , commonly associated with Neu, was upregulated across multiple non-neutrophilic populations while a restricted pattern of Lcn2 upregulation was found in specific myeloid progenitors and immature B cells. Notably, both proteins also showed an heterogeneously increased trend in patients’ rib fragments. Finally, we demonstrated that Tasquinimod, known for its S100A9 immunomodulatory effect, in combination with anti-PD-L1 immunotherapy significantly reduced tumor burden in the immunotherapy-refractory LLC model. Conclusions Lung cancer promotes emergency granulopoiesis by intrinsic HSPC reprogramming towards a less apoptotic profile with Neu bias. Our findings further suggest that the HSPC retention axis CXCL12/CXCR4 is affected, warranting further investigation into the remote manipulation of the stromal BM niche during lung cancer progression. The altered expression of S100a9 and Lcn2 across the non-neutrophilic myeloid and lymphoid hematopoietic populations identifies additional molecular alterations associated with the tumor-bearing state. Finally, Tasquinimod treatment, particularly in combination with anti-PD-L1 immunotherapy, was associated with reduced tumor burden in vivo. Together, these findings support further investigation into BM-associated alterations and their potential contribution to immunotherapy-refractory lung cancer.

Journal of Experimental & Clinical Cancer Research
Good health and well-being
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon